A Community of Practice (CoP) for small- to medium-sized trial sponsors is in the offing
Halloran Consulting Group (Boston), a fast-growing advisory firm on managing clinical trials, has joined the Metrics Champion Consortium (MCC; Boston) to help building up the Small/Midsize Sponsor CoP, said to be the first such effort for the life sciences community. Laurie Halloran, CEO, says that her company’s partnership is a “natural fit” in that more than half of the company’s clients are in that size range. The company has been providing administrative and advisory support to help clients manage trails and meet FDA review and approval requirements; it specializes in, among other things, properly managing the financials of clinical trials.
MCC is a nearly decade-old nonprofit that provides training, benchmarking and advice on improving clinical trial operations. It has over 80 members among drug companies, contract research organizations and service providers to the clinical trials business. Over the past year, it has been establishing workgroup for small- to mid-size firms; in the recent past, it has published surveys and guidance documents for trial master files, key performance indicators, risk-based monitoring of trials and related topics.
Together, the two are sponsoring a complimentary webinar, “How can Small Companies Benefit from Efforts to Standardize,” on Dec. 1. More information is available here.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
New UK Consortium Obtains $1.34M Grant to Launch Automated Cell Therapy Manufacturing Platform
July 15th 2025Cellular Origins, CGT Catapult, and Resolution Therapeutics partner up to design a fully automated, scalable CGT manufacturing solution, with the goal of accelerating patient access to cell therapies.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.